Market News & Trends
Glaucoma Treatment Market Value Will Grow Moderately to $3 Billion
The treatment market for glaucoma will rise in value from $2.4 billion in 2013 to approximately $3 billion by 2023 across the seven major markets…
Halozyme Enters Lucrative Global Collaboration & Licensing Agreement
Halozyme Therapeutics, Inc. recently announced a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE…
Recipharm Signs Partnership Agreement With Follicum
Recipharm recently announced it has signed a partnership agreement with Follicum AB in preparation for a clinical trial of the drug candidate FOL-005. Recipharm has…
EMD Millipore Introduces Compaction Technology to Improve Solubility
EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, recently introduced a new technology that compacts dry powder cell culture media into…
Unchained Labs Announces Major Acquisition; Second of the Year
Unchained Labs recently announced the acquisition of AVIA Biosystems, the developer of the Isothermal Chemical Denaturation (ICD) system for measuring biologic stability. This is the…
Oxis Biotech Files US Patent Application Covering Additional Analogs
Oxis Biotech, Inc. recently announced it has filed a US patent application covering additional analogs of the company's lead compound, OXS-4235, a potent p62/Sequestosome 1…
Egalet Announces Top-Line Study Results
Egalet Corporation recently announced top-line results from a randomized, four-way crossover alcohol-interaction study in healthy male and female moderate drinkers with Egalet-002, an abuse-deterrent, extended-release,…
Drug Abuse Triggers Regulations to Push the Development of Tamper-Resistant Opioid Formulations for Pain Management
The pain market is currently dominated by opioid analgesics, which have well-known side effects, such as addiction and constipation. However, a $10-billion market exists for…
Mapi Pharma Closes $10-Million Investment
Mapi Pharma Ltd. Recently announced that Shavit Capital has led an investment round of $10 million in the company in a Series A financing round…
Entolimod May be a Promising Treatment Option for Many Solid Tumors
A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute (RPCI) shared results from the first clinical…
EMD Millipore to Acquire Exclusive Rights to Singulex's Technology
EMD Millipore and Singulex recently announced they have entered into a definitive agreement under which EMD Millipore will control and manage the Singulex Life Science…
Alligator Bioscience AB Phase I Trial Benefits From Cobra Biologics' maxXpress Platform
Cobra Biologics, an international CDMO of biologics and pharmaceuticals, has developed a cell line for Alligator Bioscience, a Swedish biotechnology company, expressing monoclonal antibodies for…
NanoString Announces Significant Clinical Research Collaboration
NanoString Technologies and Merck recently announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential…
IGI Laboratories Announces Third ANDA Submission of 2015
IGI Laboratories, Inc. recently announced it has submitted its third abbreviated new drug application (ANDA) to the US Food and Drug Administration (FDA) of 2015,…
Pharmaxis to Focus on Partnering; Sells Phase I Drug Candidate to Boehringer
Pharmaxis recently announced its transition to a strategic business plan with an increased focus on innovation and partnering in order to generate value. The new…
DURECT Corporation Announces Positive Study Results
DURECT Corporation recently announced it has obtained positive results from a multi-dose Phase I clinical trial with an oral formulation of DUR-928, the lead molecule…
Novozymes Biopharma Enables Stable Formulation of Serendex Pharmaceutical’s Drug
Denmark-based Serendex Pharmaceuticals recently announced they will initiate Phase I clinical trials for their Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) drug candidate, Molgradex. The drug…
Pluristem Announces Significant Advancement to its Clinical Development Plan
Pluristem Therapeutics Inc. (PSTI) recently announced a significant advancement to its clinical development plan: the PLX cell program in critical limb ischemia has been selected…
Eleven Biotherapeutics Announces Top-Line Results From Pivotal Phase III Study
Eleven Biotherapeutics, Inc. recently announced top-line results from the OASIS study, the company’s first pivotal Phase III study of its lead drug candidate, EBI-005, in…
First Patient Dosed in Phase II Study of Tipifarnib
Kura Oncology, Inc. recently announced that the first patient has been dosed in the Phase II clinical trial of tipifarnib in patients with locally advanced…
